Cargando…
Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial
BACKGROUND: This study aimed to assess the efficacy of topiramate, a glutamate-modulating agent, in patients with treatment-resistant obsessive-compulsive disorder (OCD) as an adjunct to serotonin reuptake inhibitors (SRIs). MATERIALS AND METHODS: Thirty-eight patients with refractory OCD, were rand...
Autores principales: | Afshar, Hamid, Akuchekian, Shahla, Mahaky, Behzad, Zarean, Elham |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4274576/ https://www.ncbi.nlm.nih.gov/pubmed/25538783 |
Ejemplares similares
-
A randomized clinical trial: Comparison of group acceptance and commitment therapy with drug on quality of life and depression in patients with obsessive–compulsive disorder
por: Ebrahimi, Amrollah, et al.
Publicado: (2022) -
Efficacy of N-Acetylcysteine Augmentation on Obsessive Compulsive Disorder: A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial
por: Ghanizadeh, Ahmad, et al.
Publicado: (2017) -
Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]
por: Carey, Paul D, et al.
Publicado: (2005) -
Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]
por: Carey, Paul D, et al.
Publicado: (2005) -
The Effect of Atorvastatin on Obsessive-compulsive Symptoms of Refractory Obsessive-compulsive Disorder (Add-on Therapy)
por: Akouchekian, Shahla, et al.
Publicado: (2018)